Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors

NCT06736275 is registered in ClinicalTrials.gov with Jiangsu Nutai Biologics Co., Ltd as lead sponsor.

NCT NCT06736275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06736275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
Lead sponsor
Jiangsu Nutai Biologics Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
September 2, 2024
Completion date
December 9, 2027
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, cachexia